Positive results using Affitech-identified human antibody that blocks VEGF binding to VEGF receptor 2
26 Apr 2007 -
Affitech AS announced that Peregrine Pharmaceuticals, Inc. reported positive in vivo test results of R3, a fully human monoclonal antibody developed by Affitech, in a pancreatic cancer model at the recently concluded Centennial Annual Meeting of the American Association for Cancer Research (AACR). R3 has been designed by the two companies for selective blocking of VEGF (vascular endothelial growth
factor) binding to VEGF receptor 2, as opposed to other anti-angiogenic agents which block activity of both VEGF receptors. The R3 antibody, which was generated by Affitech's phagemid antibody library screening method, when tested by Peregrine on a pancreatic cancer model, showed significant reduction of the growth, vascularization and macrophage infiltration of pancreatic tumors in mice. This is the first antibody from Affitech's library that has been tested in a preclinical development model. Peregrine announced that the positive results of R3 antibody support the Company's intent to progress its anti-VEGF program towards clinical trials.
Top
Contact
Print version
PDF version
Send article
RSS-Feed
